Medical Condition News

RSS

Researchers show Simvastatin prevents Parkinson's disease from progressing further

Simvastatin, a commonly used, cholesterol-lowering drug, may prevent Parkinson's disease from progressing further. Neurological researchers at Rush University Medical Center conducted a study examining the use of the FDA-approved medication in mice with Parkinson's disease and found that the drug successfully reverses the biochemical, cellular and anatomical changes caused by the disease.

30 Oct 2009

Increased fructose intake is associated with elevated blood pressure

A diet high in fructose increases the risk of developing high blood pressure (hypertension), according to a paper being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, California. The findings suggest that cutting back on processed foods and beverages that contain high fructose corn syrup (HFCS) may help prevent hypertension.

30 Oct 2009

NIH launches randomized trail to determine whether lower BP goal cuts the risk of heart and kidney diseases

The National Institutes of Health is launching a large multicenter randomized clinical trial to determine whether maintaining blood pressure levels lower than current recommendations further reduces the risk of cardiovascular and kidney diseases, or age-related cognitive decline.

30 Oct 2009

Aerobics and resistance training exercise prevent visceral fat gain

A study conducted by exercise physiologists in the University of Alabama at Birmingham (UAB) Department of Human Studies finds that as little as 80 minutes a week of aerobic or resistance training helps not only to prevent weight gain, but also to inhibit a regain of harmful visceral fat one year after weight loss.

30 Oct 2009

Celera to use Medical Therapies' midkine patent portfolio for development of novel lung cancer diagnostics

Celera Corporation, a health care company focused on genetics, and Medical Therapies Limited (ASX:MTY), a biotechnology company developing midkine-related diagnostic and therapeutic products, have entered into an exclusive license agreement for the use of MTY’s midkine patent portfolio for the development of novel lung cancer diagnostics.

30 Oct 2009

Vitamin D deficiency may account for increased risk of end-stage renal disease in African Americans

Low levels of vitamin D may account for nearly 60 percent of the elevated risk of end-stage renal disease (ESRD) in African Americans, according to a report in the December Journal of the American Society of Nephrology (JASN).

30 Oct 2009

USC to develop stem cell-based treatment for age-related macular degeneration with CIRM grant

Physician-researchers at the University of Southern California (USC) received a nearly $16 million grant from the California Institute of Regenerative Medicine (CIRM) to fund the development of a stem cell-based treatment for age-related macular degeneration, the leading cause of vision loss and blindness among the elderly.

29 Oct 2009

CIRM awards Cedars-Sinai Heart Institute $5.5 million grant for development of cardiac stem cell therapies

A team of Cedars-Sinai Heart Institute stem cell researchers led by Eduardo Marb-n, M.D., Ph.D. has been awarded a four-year, $5.5 million grant from the California Institute of Regenerative Medicine (CIRM) to fund research leading to clinical trials of new treatments for heart attack patients.

29 Oct 2009

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

Celldex Therapeutics, Inc. today announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder and pancreatic cancer.

29 Oct 2009

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

The management of dyslipidemia continues to evolve and despite improvements in recurrent cardiovascular events and a decrease in cardiac mortality, cardiovascular disease (CVD) still represents the major burden of disease in this country.

29 Oct 2009

World’s first Cesium-131 lung implants performed

IsoRay, Inc. announced today that starting on August 12, 2009, Dr. Bhupesh Parashar from the Department of Radiation Oncology, and Dr. Nasser Altorki of the Department of Cardiothoracic Surgery at Weill Cornell Medical Center performed the world’s first Cesium-131 lung implants.

29 Oct 2009

Alnylam Pharmaceuticals announces participation in a $2.4M cardiovascular disease research grant

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today its participation in a $2.4 million research grant awarded to the University of Pennsylvania under the “American Recovery and Reinvestment Act of 2009”. The new grant will fund research over two years in the laboratories of Daniel Rader, M.D. of the University of Pennsylvania School of Medicine, Sekar Kathiresan, M.D. of Massachusetts General Hospital (MGH) and Harvard Medical School, and Alnylam.

29 Oct 2009

Amorfix Life Sciences achieves 100% specificity in using EP-vCJD Blood Screening Assay

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, today announced it has achieved 100% specificity (no reproducible false positive results) upon testing 19,000 blood donations for variant Creutzfeldt-Jakob Disease ("vCJD") with the EP-vCJD(TM) Blood Screening Assay at l'Etablissement Français du Sang de Pyrénées Méditerrannée ("EFS-PM") in Montpellier, France.

29 Oct 2009

Positive results from Genta's Phase 3 trial of Genasense

Genta Incorporated today announced top-line results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine administered with or without Genasense® in patients who have not previously received chemotherapy.

29 Oct 2009

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.

29 Oct 2009

Seminar on multiple myeloma

MediCom Worldwide, Inc., an accredited provider of continuing medical education for physicians, pharmacists, and nurses, announces a Friday Satellite Symposium on Multiple Myeloma Preceding the 51st ASH Annual Meeting entitled Unifying Practice Patterns Among Academic and Community Clinicians: Focus on Myeloma.

29 Oct 2009

Publix Supermarkets to sell HeartSavior and LipidShield Plus

New Health Corp. is proud to announce that HeartSavior(TM) and LipidShield® Plus are now available at Publix Supermarkets.

29 Oct 2009

Grassroots Health and the University of Toronto School of Medicine to host a Vitamin D symposium

Vitamin D Deficiency - linked to significantly higher rates of most cancers, heart disease, autoimmune diseases such as multiple sclerosis, and even flu - affects 97 per cent of Canadians. Yet fewer than 3 per cent of Canadians say they know their vitamin D blood levels.

29 Oct 2009

Non-surgical alternative treatment for moderate to advanced gum disease announced

BIOLASE Technology, Inc. today announced its new Deep Pocket Therapy with New Attachment™ using the Waterlase MD™ and patented Radial Firing Perio Tips™ (RFPT) for a non-surgical alternative treatment for moderate to advanced gum disease.

29 Oct 2009

Fondation Jacques-F. Gougoux donates over $57,000 to the Quebec Division of the Multiple Sclerosis Society

The Quebec Division of the Multiple Sclerosis Society of Canada is delighted to be able to count on the Fondation Jacques-F. Gougoux in improving the quality of life for people with multiple sclerosis and their families. A donation of $57,386, spread over 15 years, will enable the MS Society to make some of its services more accessible.

29 Oct 2009

Medical Condition News

Researchers show Simvastatin prevents Parkinson's disease from progressing further

Increased fructose intake is associated with elevated blood pressure

NIH launches randomized trail to determine whether lower BP goal cuts the risk of heart and kidney diseases

Aerobics and resistance training exercise prevent visceral fat gain

Celera to use Medical Therapies' midkine patent portfolio for development of novel lung cancer diagnostics

Vitamin D deficiency may account for increased risk of end-stage renal disease in African Americans

USC to develop stem cell-based treatment for age-related macular degeneration with CIRM grant

CIRM awards Cedars-Sinai Heart Institute $5.5 million grant for development of cardiac stem cell therapies

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

World’s first Cesium-131 lung implants performed

Alnylam Pharmaceuticals announces participation in a $2.4M cardiovascular disease research grant

Amorfix Life Sciences achieves 100% specificity in using EP-vCJD Blood Screening Assay

Positive results from Genta's Phase 3 trial of Genasense

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Seminar on multiple myeloma

Publix Supermarkets to sell HeartSavior and LipidShield Plus

Grassroots Health and the University of Toronto School of Medicine to host a Vitamin D symposium

Non-surgical alternative treatment for moderate to advanced gum disease announced

Fondation Jacques-F. Gougoux donates over $57,000 to the Quebec Division of the Multiple Sclerosis Society

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News